首页 > 硕士 > 管理学 > 正文

药品集中招标采购对制药行业市场集中度的影响研究

Analysis on the Impacts of the Centralized Bidding and Purchase of Medicine on the Concentration Rate of Pharmaceutical Industry Market

作者: 专业:社会医学与卫生事业管理 导师:施少斌 年度:2015 学位:硕士  院校: 广州中医药大学

Keywords

Centralized Bidding and Purchase of Medicine, Pharmaceutical Industry, Market Concentration Rate, Impacts

        目的:研究旨在分析我国药品集中招标采购制度大环境下,我国制药行业的集中度现状、趋势,以及在不同模式药品采购制度下,各省份(地区)药品中标集中度的差异,进而了解药品集中招标采购给我国制药行业市场集中度带来的影响,分析影响因素有哪些,影响机制如何。最终得出有关我国药品集中招标采购政策对制药行业市场影响的相关结论,从促进医药行业产业调整、实现药品行业规模生产,以及提升制药行业市场集中度的角度出发,提出有利于完善药品集中招标采购制度和提高我国制药行业市场集中度的相关建议。方法:鉴于我国特殊的药品集中招标采购政策背景,在分析药品制度对制药行业集中度的影响机制中,本研究创新地提出中间影响变量指标——药品采购中标集中度。本研究以药品集中招标采购制度、我国制药行业集中度、我国部分省份药品集中招标采购实施方案指导下的药品中标集中度为研究对象,从《中国统计年鉴》、《中国药物统计年鉴》获取制药行业集中度等相关数据,并从广东省医药采购中心获得我国15个省份21次药品集中招标采购中标情况的数据,采用文献检索循证分析法、多元统计分析法、指标分析法、对比分析法进行实证研究。实证结果揭示了药品集中招标采购制度对制药行业市场集中度的影响。结果:第一、总结了我国药品集中招标采购的历史沿革与国内典型的药品采购模式。第二、分析了我国制药行业总体市场规模、集中度现状和趋势,并与世界制药行业和国际具有代表性国家的制药行业集中度进行对比分析。第三、对2009年广东、广西、四川、湖北、河南、福建、云南七省和2011年广东、广西、四川、湖北、河南、福建、江西、陕西、安徽、新疆、江苏、浙江、山东、湖南十四省的药品集中招标采购的中标药品情况进行实证研究,分析药品集中招标采购各方面相关内容对药品采购中标集中度和制药行业集中度的影响。结论:我国制药行业市场集中度总体水平偏低,并且在药品集中招标采购制度实施后我国制药行业集中度有所下降。随着医药行业的不断发展变化,我国制药产业的企业所有权结构逐渐发生变化,生产要素和资源逐渐从国有控股企业流出,流向民资控股企业,但国有控股企业的行业主导领先地位并未发生改变。研究的实证分析结果表明,药品集中招标采购制度通过影响药品中标集中度间接影响制药行业集中度。在药品集中招标采购中采用量价挂钩或者单一货源承诺的招标形式,在药品集中招标采购实施方案中明确规定与企业规模、竞争实力相关内容的省份药品采购中标集中度较高。招标药品数量少、中标价格低的药品集中招标采购药品中标集中度较高。同时,充分发挥市场调节和政府监管作用,允许制药企业合理的利润空间,增强制药企业在药品集中招标采购过程中的话语权,防止药品集中招标采购的地方保护行为,将有利于提高药品集中招标采购的中标集中度。
    ObjectiveThis study is to analyze under the environment of centralized bidding and purchase of medicine procurement system in our country, the status quo and trend of the pharmaceutical industry concentration and the differences of biding and purchase accepted concentration rate in different patterns of centralized bidding and purchase of medicine in different provinces (regions). Basis on the research result, we can understand the impact of the centralized bidding and purchase of medicine on the pharmaceutical industry market concentration rate, what the influence factors are, and how the influence mechanism is working. Finally it draws some conclusion about the impact of the centralized bidding and purchase of medicine on the pharmaceutical industry market concentration rate. Then on this basis, and from the point of improving the pharmaceutical industry market concentration, promoting the pharmaceutical industry adjustment and realizing the drugs industry scale production, the study puts forward some suggestion about developing the centralized bidding and purchase of medicine procurement system and enhancing market concentration of pharmaceutical industry.MethodsIn view of special medical policy background of centralized bidding and purchase of medicine in our country, while analyzing the mechanism of the impact of the centralized bidding and purchase of medicine on the pharmaceutical industry market concentration, our study puts forward an innovative influence variables index-the biding and purchasing accepted concentration rate. The research takes the centralized bidding and purchase of medicine procurement implementation scheme, the concentration of pharmaceutical industry in our country, and the centralized bidding and purchase of medicine procurement in some provinces in our country as the research object. The study collected the pharmaceutical industry concentration data from the China statistical yearbook, China’s drug statistical yearbook, and 21 times drug centralized bid procurement result data of 15 provinces in our country from Guangdong medicine bidding and procurement center. Finallly, the study launch an empirical research about the drug centralized bid procurement system impact on market concentration of pharmaceutical industry by using the literature retrieval of evidence-based analysis method, multivariate statistical analysis method, index analysis method, contrast analysis method.ResultsFirstly, the historical evolution of the centralized bidding and purchase of medicine procurement system in our country and domestic typical mode of drug purchase were summarized. Secondly, this study anylyzed the overall market size, present situation and the trend of pharmaceutical industry market concentration in China, and compared the pharmaceutical industry concentration between domestic and some international typical countries in the world. Thirdly, the study lauches empirical analysis on the situation of centralized bidding and purchase of medicine in Guangdong, Guangxi, Sichuan, Hubei, Henan, Fujian, Yunnan seven provinces in 2009, and in Guangdong, Guangxi, Sichuan, Hubei, Henan, Fujian, Jiangxi, Shanxi, Anhui, Xinjiang, Jiangsu, Zhejiang, Shandong, Hunan 14 province in 2011. Through the conclusion of empirical analysis, we can understand how the various aspects of the centralized bidding and purchase of medicine bidding and procurement system influences on the pharmaceutical industry market concentration. ConelusionThe level of pharmaceutical industry market concentration in China is in low degree, and it has a fallen after the implementation of centralized bidding and purchase of medicine procurement system. With the continuous development of the pharmaceutical industry, the enterprise ownership structure of pharmaceutical industry in China has been gradually changed, the production factors and resources has also flow from state-owned enterprises to private enterprises gradually. But the situation of state-owned enterprises dominating the leading position has not changed. The results of empirical analysis in our research shows that the policy of centralized bidding and purchase of medicine in our country effects market concentration rate of pharmaceutical industry by indirect effecting the biding and purchasing accepted concentration rate. In the centralized bidding and purchase of medicine, the provinces with hooking the quantity and price or single supply bidding form of commitment, explicitly stipulating some rules about enterprise scale and competitiveness in the centralized bidding and purchase of medicine procurement implementation scheme, and the lower winning bid price and less quatity of medicine purchase in the drug centralized biding has the higher pharmaceutical industry market concentration rate. At the same time, playing a full role of market regulation and government regulation, allowing the pharmaceutical enterprise reasonable profit space, strengthen the voice of pharmaceutical enterprises in the process of the centralized bidding and purchase of medicine, preventing the drug centralized bid procurement from local protectionism will be beneficial to improve the biding and purchasing accepted concentration rate.
        

药品集中招标采购对制药行业市场集中度的影响研究

摘要3-5
Abstract5-7
引言11-14
第一章 理论回顾与文献评述14-27
    第一节 相关概念与理论工具14-19
        一、药品集中招标采购14
        二、市场集中度的理论与指标14-19
    第二节 文献研究19-27
        一、药品采购相关文献研究19-22
        二、市场集中度相关文献研究22-24
        三、药品集中招标采购与药品市场集中度相结合的相关研究24-25
        四、未来的研究趋势25-27
第二章 药品采购模式分析27-30
    第一节 我国药品采购的历史沿革27-28
        一、计划经济时期(1949-1984年)27
        二、计划经济向市场经济的过渡时期(1985-1999年)27
        三、全面推行集中采购阶段(2000-2008年)27-28
        四、医改背景下的集中采购(2009年至今)28
    第二节 我国典型的药品采购模式分析28-30
第三章 我国制药行业市场集中度30-40
    第一节 我国制药行业规模30-34
        一、我国医药工业资产总额30-31
        二、我国医药工业企业单位数量31-33
        三、我国医药工业从业人员数量33-34
    第二节 我国制药行业市场绝对集中度现状及变化趋势分析34-40
        一、我国制药行业市场集中度变化的三个阶段35
        二、我国制药行业市场集中度在药品集中招标采购政策实施后较实施前低35-36
        三、我国制药行业市场绝对集中度整体水平偏低36-37
        四、制药工业100强企业中各区间企业竞争力在发生变化37-40
第四章 实证分析40-60
    第一节 样本、数据与集中度衡量指标40-41
        一、样本与数据来源40
        二、集中度衡量指标40-41
    第二节 广东省医疗机构药品阳光采购的药品中标集中度与区域市场集中度41-47
        一、广东省药品招标采购的历史沿革41-42
        二、2009年广东省医疗机构药品阳光采购的特点42-43
        三、广东省医疗机构药品阳光采购制度实施下的市场集中度与中标集中度43-47
    第三节 不同采购模式下的药品集中招标采购中标集中度47-53
        一、2009年我国七省药品集中招标采购中标集中度47-48
        二、2011年我国十四省药品集中招标采购中标集中度48-50
        三、我国六省两次药品招标采购中标集中度对比分析50-52
        四、药品集中招标采购中标集中度与制药行业集中度52-53
    第四节 药品集中招标采购对药品中标集中度的影响分析53-60
        一、变量定义与研究设计53-55
        二、变量的统计分析结果55-58
        三、回归结果与分析58-60
第五章 结论与建议60-68
    第一节 本文主要结论60-63
        一、药品集中招标采购制度通过影响药品中标集中度间接影响制药行业集中度60
        二、我国制药行业市场集中度在药品集中招标采购制度实施后有所下降60
        三、我国制药行业市场集中度总体水平偏低60-61
        四、我国制药产业的企业所有权结构逐渐发生变化61
        五、招标药品数量少、药品中标价格低的药品集中招标采购药品中标集中度较高61-62
        六、量价挂钩或者单一货源承诺制有利于提高我国制药行业集中度62
        七、药品采购方案中明确企业规模等相关规定利于提高药品中标集中度62
        八、增强医药企业的谈判能力及谈判话语权有利于制药行业集中度的提高62-63
        九、以省级为单位的药品集中招标采购采购可能存在地方企业保护行为63
    第二节 关于完善我国药品集中招标采购制度的相关建议63-68
        一、明确药品集中招标采购政策的核心目标与意义63-64
        二、由政府主导的药品集中招标采购应同时充分发挥市场机制的作用64-65
        三、允许制药企业合理的利润空间有利于促进我国药品行业的发展65
        四、完善各省药品集中招标采购实施方案,促进我国制药行业集中65-67
        五、加强监管机制,为医药行业发展营造良好的产业环境67
        六、防止药品集中招标采购的地方保护行为67-68
结语68-69
参考文献69-73
附录73-75
致谢75-77
统计学审核证明77
        下载全文需50


本文地址:

上一篇:苯丙胺类兴奋剂依赖者攻击性与家庭因素相关性研究
下一篇:基于患者期望与感知的医疗服务质量评价与改进研究

分享到: 分享药品集中招标采购对制药行业市场集中度的影响研究到腾讯微博           收藏
评论排行
公告